Jenkins, Valerie
Brighton and Sussex Medical School · University of Sussex
7 papers on CoChatORCID 0000-0001-8939-0081
Most cited papers
- Verified
Efficacy of a Cancer Research UK communication skills training model for oncologists: a randomised controlled trial
Fallowfield, L., Jenkins, V., Farewell, V., Saul, J., Duffy, A., & Eves, R. (2002) · The Lancet
Patient-Provider Communication in HealthcareInnovations in Medical Education
Cited by 854
- Verified
Information needs of patients with cancer: results from a large study in UK cancer centres
Jenkins, V, Fallowfield, L., & Saul, J. (2001) · British Journal of Cancer
Patient-Provider Communication in HealthcareHealth Literacy and Information Accessibility
Cited by 845
- Verified
Psychiatric morbidity and its recognition by doctors in patients with cancer
Fallowfield, L., Ratcliffe, D., Jenkins, V, & Saul, J. (2001) · British Journal of Cancer
Cancer survivorship and carePatient-Provider Communication in Healthcare
Cited by 694
- Verified
Truth may hurt but deceit hurts more: communication in palliative care
Fallowfield, L. J., Jenkins, V. A., & Beveridge, H. A. (2002) · Palliative Medicine
Palliative Care and End-of-Life IssuesPatient-Provider Communication in Healthcare
Cited by 498
- Verified
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology
HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes
Cited by 230
- Verified
Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study
Fallowfield, L., Osborne, S., Langridge, C., Monson, K., Kilkerr, J., & Jenkins, V. (2015) · The Breast
HER2/EGFR in Cancer ResearchHealth Systems, Economic Evaluations, Quality of Life
Cited by 34
- Verified
Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
Fallowfield, L. J., Catt, S. L., May, S. F., Matthews, L., Shilling, V. M., Simcock, R., Westwell, S., & Jenkins, V. A. (2017) · Supportive Care in Cancer
Patient-Provider Communication in HealthcarePalliative Care and End-of-Life Issues
Cited by 25
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free